MONTREAL and CHARLOTTE, N.C., April 16, 2019 /CNW/ -- Milestone Pharmaceuticals, a late-stage biopharmaceutical company developing acute therapies for the treatment of episodic cardiovascular conditions, today announced the appointment of Paul Edick as Chairman of its Board of Directors. Mr. Edick currently serves as Chairman and Chief Executive Officer of Xeris Pharmaceuticals, a publicly traded specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations.
"It is a pleasure to welcome Paul as Chairman of the Milestone Board of Directors at this important time in the Company's evolution," said Joseph Oliveto, President and Chief Executive Officer of Milestone Pharmaceuticals. "Paul's extensive experience as an executive leader at a range of development and commercial stage pharmaceutical companies will be invaluable as we continue to advance our Phase 3 program of etripamil for paroxysmal supraventricular tachycardia (PSVT), a common and recurring disorder of the heart. I look forward to his contributions and insight as we lay the groundwork to transition Milestone into a commercial entity."
"Milestone has the potential to make a significant, meaningful impact for patients suffering from cardiovascular disease," said Mr. Edick. "It is with great honor that I assume the role of Chairman of the Board as the Company moves closer to the potential commercialization of etripamil for PSVT and ultimately expands its pipeline into additional cardiovascular indications."
Prior to Xeris Pharmaceuticals, Mr. Edick was Founding Partner of 3G Advisors, a consultancy to the pharmaceutical, healthcare, and healthcare investor communities. He previously served as the Chief Executive Officer of Durata Therapeutics (acquired by Actavis plc in November 2014), a biopharmaceutical company developing antibiotics to treat infectious diseases. Prior to Durata, Mr. Edick was Chief Executive Officer of Ganic Pharmaceuticals. Prior to Ganic, Mr. Edick served as Chief Executive Officer at MedPointe Healthcare, Inc. where he oversaw the company's developments as it was eventually sold to Meda, AB. He also has extensive industry experience with leading consumer, pharmaceutical and healthcare organizations including Pharmacia and Searle Pharmaceuticals, where he led the commercialization and launch planning for Celebrex®. Mr. Edick currently serves as the Chairman of the Board for Iterum Therapeutics Limited. Mr. Edick has previously served on a number of pharmaceutical and healthcare company boards including Circassia Pharmaceuticals Plc, Sucampo Pharmaceuticals, Inc., Durata Therapeutics, NewLink Genetics Corp., Neos Therapeutics, Inc. and PDL BioPharma, Inc. Mr. Edick received a B.A. degree in Psychology from Hamilton College.
About Milestone Pharmaceuticals
Milestone, headquartered in Montreal, Canada with a U.S. subsidiary in Charlotte, N.C., is a late-stage biopharmaceutical company focused on developing an investigational new drug intended to provide rapid-onset and short-acting treatment of paroxysmal supraventricular tachycardia (PSVT) episodes and other episodic conditions.
For more information, visit www.milestonepharma.com.
SOURCE Milestone Pharmaceuticals USA, Inc.